Collectively, our data illustrate that the activation of the FGF-2-based autocrine loop in GISTs is a potent mechanism modulating GIST responses to KIT inhibition and maintaining resistance to IM. This evidence concerns the gene FGF2 and gastrointestinal stromal tumor.